OS Therapies Inc (OSTX)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$1.15-0.86%
Close 2026-11-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · OSTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
OSTX — capital allocation — The New Warrants and New Warrant
Dated 2026-10-19
The New Warrants and New Warrant Shares are being offered and sold by the Company in reliance upon an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D promulgated thereunder. Neither the New Warrants nor the New Warrant Shares have been registered under the Securities Act or applicable state securities laws, and such securities may not be offered or sold in the United States absent registrat…
Why it matters: OSTX is loss-making and has used warrant funding, tax credits, and delayed vendor bills. Cash timing matters as it advances Herlystic.
Worry ifThe company reports enough cash and committed funds for planned regulatory filings and trial work through 2027. It needs no new financing and has no overdue vendor bills.
Less concerning ifThe company raises capital for near-term costs, reports a cash shortfall, or cannot pay vendor bills on time in Q2 2027.
Why it matters: The company says the refund will help fund research and launch work. A delay could tighten cash for key milestones.
Watch forThe company reports that HMRC paid the accrued £7 million R&D tax credit in early 2027.
Also watch forThe filing is not submitted in Q4 2026, or the refund is not received in early 2027 as planned.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$206 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $734 loss on $10,000 · 7.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,866 loss on $10,000 · 48.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.